Press Release 5th November 2019
CME Limited announce today that the company has been awarded the contract to manufacture an automated clinical trial line, which will be the first major piece of equipment to be installed and developed within the new Medicines Manufacturing Innovation Centre.
The new centre will be located in Renfrewshire, Scotland and is a collaboration between CPI, University of Strathclyde, UK Research and Innovation, Scottish Enterprise, AstraZeneca and GlaxoSmithKline (GSK).
CME’s contribution to this prestigious project began when the company secured an initial contract for the design element of a complete bespoke system capable of receiving orders, filling bottles with the appropriate number of tablets or capsules of the requisite drug and strength, labelling bottles and consolidating those orders.
(CME’s automated clinical trial line will be the first major piece of equipment to be installed at the new Medicines Manufacturing Innovation Centre)
CME’s innovative design solution for filling bottles with tablets or capsules, whilst vastly reducing the risk of cross contamination of the bottles and the surrounding equipment / environment was instrumental in securing both the initial design contract, and now this new contract for the manufacture of the automated clinical trials line.
Paul Knight, Managing Director of CME Limited commented: ”We are delighted to have been awarded the contract to manufacture this system, which reinforces our contribution as a key partner in this project. This is an exciting project which targets the use of new and disruptive technologies to help bring medicines to market more quickly, through the adoption of Just in Time (JIT) manufacture & supply.”
It is expected that the automated platform and data integration solutions will be delivered in the second quarter of 2021.
